Pharmadrug Inc (CNSX:BUZZ) is researched by Proactive analyst, Ed Stacey, who joins Katie Pilbeam to explain the investment case for the specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs.
Stacey takes viewers through the three business segments, firstly, the European cannabis space, where Pharmadrug is an EU-GMP approved distributor of medical cannabis in the German market with a Class 1 Narcotic license.
Secondly in the retails psychedelics domain, Pharmadrug has established a retail brand focussed on the Netherlands-based market for legally sold ‘magic truffles’. And thirdly, Pharmadrug also has a biotech operation focussed on plant derived pharmaceutical medicines.